Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
A migraine disorder characterized by episodes that are preceded by focal neurological symptoms.
Biomarker and diagnostic research for migraine with aura has been reported in the published literature.
22 clinical trials registered, 14 recruiting. Interventions under study include drug therapy, other interventions, and medical devices. Pipeline includes 1 PHASE4, 1 PHASE3, 2 PHASE2. Research is sponsored by a mix of industry and academic institutions.
NCT ID | Title | Phase | Sponsor | Status |
|---|---|---|---|---|
[NCT05987592](https://clinicaltrials.gov/study/NCT05987592) |
Data assembled from 3 of 12 sources · Last updated Sep 19, 2026, 6:53 PM UTC
Program availability and eligibility requirements are set by each foundation. Contact them directly to learn more about your options.
Claim this page and your organization will be listed here for patients and families to find.
BE WELL With Migraine: Brain Education and WELLness With Migraine |
NA |
Wake Forest University Health Sciences |
RECRUITING |
[NCT06674772](https://clinicaltrials.gov/study/NCT06674772) | Molecular Phenotyping of Migraine Patients According to Sex and Age Through CGRP Quantification | — | Hospital Universitari Vall d'Hebron Research Institute | RECRUITING |
[NCT07349004](https://clinicaltrials.gov/study/NCT07349004) | Neurogenetic And Hemodynamic Of Migraine Aura And Pfo | — | Azienda Usl di Bologna | RECRUITING |
[NCT05903027](https://clinicaltrials.gov/study/NCT05903027) | Gepant treAtments: EffectIveNess and tolERability (GAINER) | — | University of Florence | RECRUITING |
[NCT06409832](https://clinicaltrials.gov/study/NCT06409832) | RimegepAnt effectIvenesS and tolErability as Migraine Preventive Treatment | — | University of Florence | RECRUITING |
243 publications have been identified in PubMed for migraine with aura. Kisho has analyzed 46 by research type. Research spans Review / Meta-Analysis (48%), Epidemiology / Natural History (17%), and Other (9%).
Research Type | Count | % of Total |
|---|---|---|
Research summaries | 22 | 48% |
Disease patterns and progression | 8 | 17% |
Other research | 4 | 9% |
Laboratory research | 4 | 9% |
Testing and diagnosis research | 2 | 4% |
Patient case studies | 2 | 4% |
Clinical study results | 2 | 4% |
New treatment approaches | 2 | 4% |
Hakimzadeh Z (2026). [PMID: 41923467](https://pubmed.ncbi.nlm.nih.gov/41923467/). *Cephalalgia*. [Review / Meta-Analysis]
Cernigliaro F (2026). [PMID: 41914337](https://pubmed.ncbi.nlm.nih.gov/41914337/). *Rev Neurol*. [Review / Meta-Analysis]
Riso IL (2025). [PMID: 41307608](https://pubmed.ncbi.nlm.nih.gov/41307608/). *Curr Pain Headache Rep*. [Review / Meta-Analysis]
Kim SA (2025). [PMID: 40086807](https://pubmed.ncbi.nlm.nih.gov/40086807/). *BMJ Ment Health*. [Epidemiology / Natural History]
Borończyk M (2025). [PMID: 39979846](https://pubmed.ncbi.nlm.nih.gov/39979846/). *J Headache Pain*. [Review / Meta-Analysis]
Oncel MM (2025). [PMID: 41340021](https://pubmed.ncbi.nlm.nih.gov/41340021/). *J Headache Pain*. [Review / Meta-Analysis]
Joppeková Ľ (2025). [PMID: 40597581](https://pubmed.ncbi.nlm.nih.gov/40597581/). *J Headache Pain*. [Review / Meta-Analysis]
Grodzka O (2025). [PMID: 40229683](https://pubmed.ncbi.nlm.nih.gov/40229683/). *J Headache Pain*. [Review / Meta-Analysis]
Deng MG (2025). [PMID: 39658945](https://pubmed.ncbi.nlm.nih.gov/39658945/). *Headache*. [Epidemiology / Natural History]
Zhang PA (2025). [PMID: 40394501](https://pubmed.ncbi.nlm.nih.gov/40394501/). *J Headache Pain*. [Diagnostic / Biomarker]